[go: up one dir, main page]

MA26426A1 - PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF NEW MONOCYCLIC B-LACTAMS AND FOR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Google Patents

PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF NEW MONOCYCLIC B-LACTAMS AND FOR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Info

Publication number
MA26426A1
MA26426A1 MA24565A MA24565A MA26426A1 MA 26426 A1 MA26426 A1 MA 26426A1 MA 24565 A MA24565 A MA 24565A MA 24565 A MA24565 A MA 24565A MA 26426 A1 MA26426 A1 MA 26426A1
Authority
MA
Morocco
Prior art keywords
lactams
intermediates
processes
preparation
pharmaceutical compositions
Prior art date
Application number
MA24565A
Other languages
French (fr)
Inventor
Dr Dashyant Dhanak
Dr Deirdre Mary Hickey
Bernadette
Dr Colin Andrew Leach
Mr Colin J Theobald
Dr Robert John Ife
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608646.7A external-priority patent/GB9608646D0/en
Priority claimed from GBGB9623756.5A external-priority patent/GB9623756D0/en
Priority claimed from GBGB9625121.0A external-priority patent/GB9625121D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA26426A1 publication Critical patent/MA26426A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA24565A 1996-04-26 1997-04-24 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF NEW MONOCYCLIC B-LACTAMS AND FOR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM MA26426A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9608646.7A GB9608646D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9623756.5A GB9623756D0 (en) 1996-11-15 1996-11-15 Novel compounds
GBGB9625121.0A GB9625121D0 (en) 1996-12-03 1996-12-03 Novel compounds

Publications (1)

Publication Number Publication Date
MA26426A1 true MA26426A1 (en) 2004-12-20

Family

ID=27268259

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24565A MA26426A1 (en) 1996-04-26 1997-04-24 PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF NEW MONOCYCLIC B-LACTAMS AND FOR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Country Status (17)

Country Link
EP (1) EP0915843A1 (en)
JP (1) JP2000509049A (en)
AR (1) AR006833A1 (en)
AU (1) AU2698697A (en)
BR (1) BR9709196A (en)
CA (1) CA2252696A1 (en)
CZ (1) CZ341098A3 (en)
HU (1) HUP9901359A3 (en)
ID (1) ID16660A (en)
IL (1) IL126696A0 (en)
MA (1) MA26426A1 (en)
NO (1) NO984939L (en)
NZ (1) NZ332476A (en)
PE (1) PE64398A1 (en)
PL (1) PL329530A1 (en)
TR (1) TR199802160T2 (en)
WO (1) WO1997041098A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060805A1 (en) 2000-02-16 2001-08-23 Smithkline Beecham P.L.C. Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
SI1355644T1 (en) 2001-01-26 2006-10-31 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS50386B (en) 2001-03-28 2009-12-31 Schering Corporation, ENANTIOSELECTIVE SYNTHESIS OF INTERMEDIATE UNITS OF AZETIDINONE
US20030013699A1 (en) * 2001-05-25 2003-01-16 Davis Harry R. Methods for treating alzheimer's disease and/or regulating levels of amyloid beta peptides in a subject
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DK1429756T3 (en) 2001-09-21 2007-03-19 Schering Corp Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US20040092499A1 (en) 2002-11-06 2004-05-13 Schering Corporation Methods and therapeutic combinations for the treatment of autoimmune disorders
CN1756755A (en) 2003-03-07 2006-04-05 先灵公司 Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ATE418551T1 (en) 2003-03-07 2009-01-15 Schering Corp SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
JP5437996B2 (en) 2007-05-11 2014-03-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア How to treat skin ulcers
BRPI0721697A2 (en) 2007-05-11 2014-08-05 Univ Jefferson "METHODS FOR TREATING AND / OR PREVENTING NEURODEGENERATIVE DISEASE OR DISORDER IN AN INDIVIDUAL, TO TREAT AND / OR PREVENTING AN INDIVIDUAL WITH OR AT RISK OF VASCULAR DEMENTIA, TO TREAT AND / OR PREVENTING A BARRIERAL DISORDER OR DISORDER AN INDIVIDUAL, TO REDUCE BETA AMILOID ACCUMULATION IN THE BRAIN OF AN INDIVIDUAL, TO TREAT AND / OR PREVENT ALZHEIMER IN AN INDIVIDUAL AND TO PREVENT OR REDUCE THE RISK OF DEVELOPING ALZHHEIMER MISUSE, AND IN USE OF AND / OR LP-PLA2 PROTEIN ACTIVITY. "
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
MX2013006342A (en) 2010-12-06 2013-08-26 Glaxo Group Ltd Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by lp - pla2.
ES2847883T3 (en) 2010-12-17 2021-08-04 Glaxo Group Ltd Use of LP-PLA2 inhibitors in the treatment and prevention of eye diseases
EP2725024A4 (en) 2011-06-27 2014-12-03 Shanghai Inst Materia Medica AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE
KR20140059203A (en) 2011-07-27 2014-05-15 글락소 그룹 리미티드 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
AU2012288865B2 (en) 2011-07-27 2015-10-01 Glaxo Group Limited Bicyclic pyrimidone compounds
JP2016505053A (en) 2013-01-25 2016-02-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Bicyclic pyrimidone compounds as inhibitors of Lp-PLA2
CA2899124A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Compounds
AU2014209949B2 (en) 2013-01-25 2016-09-08 Glaxosmithkline Intellectual Property Development Limited 2,3-dihydroimidazol(1,2-c)pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (Lp-PLA2) inhibitors
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
BR112022008786A2 (en) 2019-11-09 2022-07-26 Shanghai Simr Biotechnology Co Ltd COMPOUND, COMPOSITION, USE OF COMPOUND OR COMPOSITION, AND METHOD FOR TREATMENT OR PREVENTION OF A DIABETIC COMPLICATION, DISEASE RELATED TO NEUROINFLAMMATION OR ATHEROSCLEROSIS
CN115304620A (en) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 Pyrimidone derivatives, preparation method, pharmaceutical composition and application thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
DE69222532T2 (en) * 1991-07-23 1998-02-26 Schering Corp SUBSTITUTED BETA LACTAM COMPOUNDS AS HYPOCHOLESTEROLEMIC AGENTS AND METHOD FOR THE PRODUCTION THEREOF
MY128261A (en) * 1992-10-27 2007-01-31 Merck Sharp & Dohme New substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1994013636A1 (en) * 1992-12-17 1994-06-23 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
JPH08500740A (en) * 1993-06-25 1996-01-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Lipoprotein-related phospholipase A-2, its inhibitors and their use in diagnosis and therapy
ES2159573T3 (en) * 1993-10-06 2001-10-16 Icos Corp ACETILHIDROLASA OF THE PLATE ACTIVATOR FACTOR.
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
BR9510420A (en) * 1994-12-22 2004-04-20 Smithkline Beecham Plc Replaced Azetidin-2-ones for atherosclerosis treatment
AU5014496A (en) * 1995-03-23 1996-10-08 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
NZ311684A (en) * 1995-07-01 2000-04-28 Smithkline Beecham Plc Azetidinone derivatives, preparation, and use for treating atherosclerosis
WO1997021676A1 (en) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis

Also Published As

Publication number Publication date
CZ341098A3 (en) 1999-03-17
HUP9901359A3 (en) 2000-03-28
IL126696A0 (en) 1999-08-17
PE64398A1 (en) 1999-01-06
CA2252696A1 (en) 1997-11-06
AU2698697A (en) 1997-11-19
JP2000509049A (en) 2000-07-18
TR199802160T2 (en) 1999-04-21
EP0915843A1 (en) 1999-05-19
WO1997041098A1 (en) 1997-11-06
PL329530A1 (en) 1999-03-29
NO984939L (en) 1998-12-23
NO984939D0 (en) 1998-10-23
ID16660A (en) 1997-10-30
AR006833A1 (en) 1999-09-29
BR9709196A (en) 1999-05-25
NZ332476A (en) 2000-06-23
HUP9901359A2 (en) 1999-08-30

Similar Documents

Publication Publication Date Title
MA26426A1 (en) PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF NEW MONOCYCLIC B-LACTAMS AND FOR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MA23632A1 (en) PROCESS FOR THE PREPARATION OF NEW COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DZ2745A1 (en) Novel bicycloÄ2.2.1Üheptanes for their preparation and pharmaceutical compositions containing them.
MA26439A1 (en) NOVEL INDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MA26430A1 (en) NOVEL 4 (3H) -QUINAZOLINONES 2,3-DISUBSTITUTED, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2740136B1 (en) INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ID18663A (en) COMPOSITION OF PHARMACEUTICAL PLATED PHARMACEUTICALS
DZ2358A1 (en) Apide b / mtp secretion inhibiting amides, process for their preparation and pharmaceutical compositions containing them
MA26687A1 (en) 4-CARBOXYAMINO-2-METHYL-1,2,3,4-TETRAHYDROQUINOLEINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MA26620A1 (en) NEW BICYCLIC HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2729951B1 (en) NOVEL HETEROCYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MA26415A1 (en) HETEROCYCLIC COMPOUNDS, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MA26638A1 (en) NOVEL ISOTHIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MA26686A1 (en) NOVEL 4,4-BIARYLPIPERIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MA26571A1 (en) HYDROXAMIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION
FR04C0032I2 (en) NEW QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DZ2461A1 (en) New arylkylamine derivatives and pharmaceutical composition containing them.
MA26428A1 (en) NEW INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM
MA26465A1 (en) NEW QUINOLEIN DERIVATIVES AND QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DZ2699A1 (en) New erythromycin derivatives and intermediates for preparation and pharmaceutical compositions containing them.
MA26490A1 (en) NOVEL TETRAHYDROISOQUINOLEIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
MA23922A1 (en) PROCESS FOR THE PREPARATION OF NOVEL MONOCYCLIC B-LACTAM COMPOUNDS AND MEDICAMENT CONTAINING THEM
MA26417A1 (en) AZETIDINES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PT83896A (en) PROCESS FOR THE PREPARATION OF NEW CONJUGATES OF VINBLAS-TINE AND ITS DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
MA26501A1 (en) NEW QUINOLEIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM